Patrick Hwu
The University of Texas MD Anderson Cancer Center · 1,298 works · 76,461 citations · h-index 113
Top works
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
- Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
- Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
- PD-L1 Expression in Triple-Negative Breast Cancer
- Prognostic Factors That Determine the Long-Term Survival of Patients with Unresectable Metastatic Melanoma
- Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
- Indoleamine 2,3-Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation
- B cells and tertiary lymphoid structures promote immunotherapy response
- NRAS mutation status is an independent prognostic factor in metastatic melanoma
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- Unopposed Production of Granulocyte-Macrophage Colony-Stimulating Factor by Tumors Inhibits CD8+ T Cell Responses by Dysregulating Antigen-Presenting Cell Maturation
- Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
- Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).
- Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma